Graff, Jeremy

Targeting the eIF4F Translation Initiation Complex: A Critical Nexus for Cancer Development

Pelletier, J., Graff, J., Ruggero, D., & Sonenberg, N. (2015) · Cancer Research

RNA and protein synthesis mechanismsPI3K/AKT/mTOR signaling in cancer

Cited by 367

Pharmacogenetic inhibition of eIF4E-dependent Mmp9 mRNA translation reverses fragile X syndrome-like phenotypes

Gkogkas, C. G., Khoutorsky, A., Cao, R., Jafarnejad, S. M., Prager-Khoutorsky, M., Giannakas, N., Kaminari, A., Fragkouli, A., Nader, K., Price, T. J., et al. (2014) · Cell Reports

Genetics and Neurodevelopmental DisordersRNA and protein synthesis mechanisms

Cited by 201

Preclinical assessment of galunisertib (LY2157299 monohydrate), a first‐in‐class transforming growth factor‐β receptor type I inhibitor

Yingling, J. M., McMillen, W. T., Yan, L., Huang, H., Sawyer, J. S., Graff, J., Clawson, D. K., Britt, K. S., Anderson, B. D., Beight, D. W., et al. (2018) · Oncotarget

TGF-β signaling in diseasesMechanisms of cancer metastasis

Cited by 187

Characterization of LY2228820 dimesylate, a potent and selective inhibitor of p38 MAPK with antitumor activity

Campbell, R. M., Anderson, B. D., Brooks, N. A., Brooks, H. B., Chan, E. M., De Dios, A., Gilmour, R., Graff, J. R., Jambrina, E., Mader, M., et al. (2014) · Molecular Cancer Therapeutics

Melanoma and MAPK PathwaysProtein Kinase Regulation and GTPase Signaling

Cited by 121